<VariationArchive RecordType="classified" VariationID="1073743" VariationName="NC_000016.9:g.(?_9857006)_(9862956_?)del" VariationType="Deletion" Accession="VCV001073743" Version="10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-11" DateCreated="2021-05-10" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1057847" VariationID="1073743">
      <GeneList>
        <Gene Symbol="GRIN2A" FullName="glutamate ionotropic receptor NMDA type subunit 2A" GeneID="2903" HGNC_ID="HGNC:4585" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="9753404" stop="10182908" display_start="9753404" display_stop="10182908" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="9847264" stop="10276610" display_start="9847264" display_stop="10276610" Strand="-" />
          </Location>
          <OMIM>138253</OMIM>
          <Haploinsufficiency last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000016.9:g.(?_9857006)_(9862956_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="9857006" innerStop="9862956" display_start="9857006" display_stop="9862956" variantLength="5951" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_9857006)_(9862956_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_9857006)_(9862956_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.9:g.(?_9857006)_(9862956_?)del AND Landau-Kleffner syndrome" Accession="RCV001386818" Version="7">
        <ClassifiedConditionList TraitSetID="12189">
          <ClassifiedCondition DB="MedGen" ID="C0282512">Landau-Kleffner syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2023-11-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">24372385</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29961510</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12189" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5374" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Landau-Kleffner syndrome</ElementValue>
                <XRef ID="Landau-Kleffner+syndrome/4080" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009509" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APHASIA, ACQUIRED, WITH EPILEPSY</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epilepsy with neurodevelopmental defects</ElementValue>
                <XRef ID="Epilepsy+with+neurodevelopmental+defects/8322" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired aphasia with convulsive disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired epileptiform aphasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FESD</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ADRESD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RESDAD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">LKS</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Encephalopathy with Epilepsy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Speech Disorders and Epilepsy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GRIN2A-related speech disorders and epilepsy are characterized by speech disorders in all affected individuals and a range of epilepsy syndromes present in about 90%. Severe speech disorders observed can include dysarthria and speech dyspraxia, and both receptive and expressive language delay/regression; more mildly affected individuals may display subtly impaired intelligibility of conversational speech. Epilepsy features include seizure onset usually between ages three and six years, focal epilepsy with language and/or global developmental regression, and electroencephalogram (EEG) showing continuous spike-and-wave discharges in sleep or very active centrotemporal discharges. Seizure types include seizures associated with aura of perioral paresthesia, focal or focal motor seizures (often evolving to generalized tonic-clonic), and atypical absence seizures. Epilepsy syndromes can include: Landau-Kleffner syndrome (LKS), epileptic encephalopathy with continuous spike-and-wave during sleep (ECSWS), childhood epilepsy with centrotemporal spikes (CECTS), atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD), and infantile-onset epileptic encephalopathy.</Attribute>
                <XRef ID="NBK385627" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6855" />
                <XRef ID="6855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">27683935</ID>
                <ID Source="BookShelf">NBK385627</ID>
              </Citation>
              <XRef ID="1945" DB="Orphanet" />
              <XRef ID="725" DB="Orphanet" />
              <XRef ID="98818" DB="Orphanet" />
              <XRef ID="C0282512" DB="MedGen" />
              <XRef ID="MONDO:0009509" DB="MONDO" />
              <XRef Type="MIM" ID="245570" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3112826" SubmissionDate="2023-02-03" DateLastUpdated="2023-11-11" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000833.4_Deletion (Exons 13-14)|MedGen:C1832814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001587171" DateUpdated="2023-11-11" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24372385</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29961510</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 13-14 of the GRIN2A gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. A similar copy number variant has been observed in individual(s) with rolandic epilepsy (PMID: 24372385). This variant is also known as del16p13.2. This variant disrupts a region of the GRIN2A protein in which other variant(s) (p.Trp1271*) have been determined to be pathogenic (PMID: 29961510). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GRIN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_9857006)_(9862956_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1832814" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3112826" TraitType="Disease" MappingType="XRef" MappingValue="C1832814" MappingRef="MedGen">
        <MedGen CUI="C0282512" Name="Landau-Kleffner syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

